Bakker H D, Wiegman A, Defesche J C, Kastelein J J
Emma Kinderziekenhuis/Academisch Medisch Centrum, Amsterdam.
Ned Tijdschr Geneeskd. 1997 Dec 27;141(52):2548-51.
Familial hypercholesterolaemia (FH) is a congenital metabolic disorder predisposing to severe atherosclerosis resulting in coronary heart disease sometimes even at early adult age. Children with FH lack the stigmata at physical examination and measuring the cholesterol level does not always enable the clinician to make the diagnosis. In about 70% of the cases, the diagnosis of FH in childhood can be made by means of molecular-biological examination, by demonstrating the underlying defect of the LDL cholesterol receptor gene. In the remaining cases, the combination of the positive family history for cardiovascular diseases and increased total cholesterol and LDL cholesterol levels should suggest the diagnosis of FH. Pharmaceutical agents inhibiting the cholesterol synthesis have been researched very little in children and are not registered in the Netherlands. Nevertheless, drug treatment of children with FH is advisable because of the better possibilities to make a definite diagnosis and the early occurrence of coronary heart disease. If this treatment were indicated before patients reach adult age, the question arises whether screening for FH of children in families in which this disorder prevails, should not be promoted more strongly.
家族性高胆固醇血症(FH)是一种先天性代谢紊乱疾病,易引发严重的动脉粥样硬化,有时甚至在成年早期就会导致冠心病。患有FH的儿童在体格检查时没有明显特征,仅通过测量胆固醇水平,临床医生并不总能做出诊断。在大约70%的病例中,儿童期FH的诊断可通过分子生物学检查来确定,即通过检测低密度脂蛋白胆固醇受体基因的潜在缺陷来实现。在其余病例中,心血管疾病的阳性家族史以及总胆固醇和低密度脂蛋白胆固醇水平升高的情况应提示FH的诊断。抑制胆固醇合成的药物在儿童中的研究很少,在荷兰也未注册。然而,由于儿童FH更有可能做出明确诊断且冠心病发病较早,因此对患有FH的儿童进行药物治疗是可取的。如果在患者成年之前就需要进行这种治疗,那么对于FH在其中普遍存在的家庭中的儿童进行筛查是否不应得到更有力的推广,就成为了一个问题。